These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 17983259

  • 1. Celecoxib: a review of its use in the management of arthritis and acute pain.
    Frampton JE, Keating GM.
    Drugs; 2007; 67(16):2433-72. PubMed ID: 17983259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 6. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S, Klotz U.
    Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
    [Abstract] [Full Text] [Related]

  • 7. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L, Li C, Huang J, Mallen S.
    Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR, Essex MN, Zhang R.
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G.
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [Abstract] [Full Text] [Related]

  • 11. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF, Siddiqui MA.
    Drugs; 2009 Jul 30; 69(11):1513-32. PubMed ID: 19634927
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C, Soen S.
    Digestion; 2011 Jul 30; 83(1-2):108-23. PubMed ID: 21042022
    [Abstract] [Full Text] [Related]

  • 13. Celecoxib, NSAIDs and the skeleton.
    O'Connor JP, Lysz T.
    Drugs Today (Barc); 2008 Sep 30; 44(9):693-709. PubMed ID: 19137124
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population.
    Cardenas-Estrada E, Oliveira LG, Abad HL, Elayan F, Khalifa N, El-Usseini T.
    J Int Med Res; 2009 Sep 30; 37(6):1937-51. PubMed ID: 20146894
    [Abstract] [Full Text] [Related]

  • 15. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D, Goa KL.
    Drugs; 2000 Apr 30; 59(4):957-80. PubMed ID: 10804043
    [Abstract] [Full Text] [Related]

  • 16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Apr 30; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 17. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
    Song YW, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Baek HJ, Kim HA, Suh Y, Kang SW, Lee YJ, Jung HG.
    Clin Ther; 2007 May 30; 29(5):862-873. PubMed ID: 17697905
    [Abstract] [Full Text] [Related]

  • 18. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U.
    Arthritis Res Ther; 2006 May 30; 8(2):R35. PubMed ID: 16469112
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 30; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.
    Clin Ther; 2008 Dec 30; 30(12):2366-77. PubMed ID: 19167595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.